JUNSHI BIO (688180.SH): FDA Approves Clinical Trial Application for JS212 for the Treatment of Advanced Solid Tumors
Kingen Biotech (688180.SH) announced that the company has received a notification from the U.S. Food and Drug Administration (FDA) that its EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved for clinical trial application by the FDA.
JUNSHI BIO (688180.SH) announced that the company has received a notification from the Food and Drug Administration (FDA) of the United States. The clinical trial application for the EGFR/HER3 bispecific antibody-drug conjugate (code: JS212) for the treatment of advanced solid tumors has been approved by the FDA.
Related Articles
Overnight US stocks | Three major indexes fell, while Tesla, Inc. (TSLA.US) rose more than 3.5% against the market trend.
US Stock Market Move | Stock prices continued to fall, with Broadcom Inc. (AVGO.US) dropping over 4%, and its high growth performance being questioned.
US Stock Market Move | Planned $7 billion acquisition of cybersecurity company Armis ServiceNow (NOW.US) leads to a drop of over 10%
Overnight US stocks | Three major indexes fell, while Tesla, Inc. (TSLA.US) rose more than 3.5% against the market trend.
US Stock Market Move | Stock prices continued to fall, with Broadcom Inc. (AVGO.US) dropping over 4%, and its high growth performance being questioned.
US Stock Market Move | Planned $7 billion acquisition of cybersecurity company Armis ServiceNow (NOW.US) leads to a drop of over 10%
RECOMMEND
Valued At $10 Trillion, The Largest IPO In History Is Coming As SpaceX Announces Listing Plan
12/12/2025
Five Imperatives And Eight Tasks: Central Meeting Specifies Next Year’s Economic Work, Highlights Identified
12/12/2025
Over 100 New Listings In Hong Kong This Year As Total Fundraising Tops HKD 270 Billion, Eighteen “A+H” Dual Listings
12/12/2025
